Avia Pharma acquires Neubourg, a German market leader within foam-based footcare

STOCKHOLM, Sweden, 2 February 2024 – Avia Pharma Holding AB (“Avia” or the “Company”) has completed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition, Avia adds a strong dermatology brand portfolio in Germany to its platform, including, Allpresan, the German market leader in foam-based foot care. The company generates annual revenues of c. EUR 15m and has c. 70 employees.

Jacob Calmvik, Co-Founder and CEO of Avia, comments: “We are thrilled to welcome Neubourg to Avia. The acquisition fits perfectly with our strategy of acquiring strong local brands, such as Allpresan, in the DACH region.

“I believe Avia will be a very strong long-term owner of Neubourg and that they will be able to develop our brands further. The Neubourg portfolio also complements Avia’s current dermatology portfolio in a good way. I am very pleased we have been able to reach this agreement.”, says Thomas Neubourg, CEO and co-owner of Neubourg.

For further information, please contact:
Jacob Calmvik, CEO of Avia,  jacob.calmvik@aviapharma.se

About Avia Pharma
Avia is a leading Swedish OTC/Rx distribution platform with presence in the Nordics and Germany, focusing on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products with brands such as Nix, Duroferon and Allergika. With the most recent acquisition of Neubourg, Avia has an annual turnover of more than SEK 600m. Learn more about Avia Pharma at www.aviapharma.se/

About Neubourg
Neubourg was founded in 1998 and is a German dermatology company with brands such as Allpresan, Podoexpert and Onyfix. It has built its market position via proprietary technology and is recognized by pharmacies and consumers as the market leader in its niches. Learn more about Neubourg at www.neubourg.com